PTIX — Protagenic Therapeutics, Inc.\new
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1022899 ·
Last close
$0.77
Market Cap
$1.40M
52W High
$4.42
52W Low
$0.13
ADV30
22,277
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -925,103 | 2,210,769 | 4,431,101 | 2,212,646 | 6,823,789 |
| Sep 2025 | 0 | — | -1,113,864 | -869,496 | 5,002,847 | 2,722,451 | 9,703,412 |
| Jun 2025 | 0 | — | -1,208,374 | -5,057,523 | 6,488,200 | 4,096,189 | 10,462,212 |
| Mar 2025 | 0 | — | -1,448,108 | -1,440,005 | 988,650 | 872,960 | 1,076,979 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,140,350
Investing CF
$943,180
Financing CF
$4,510,070
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-08-23
Balance + Analyst (yfinance extras)
Retained Earnings
$-9,113,856
Inventory
$1,074
Receivables
$41,523
ST Investments
$0
EBIT TTM
$-8,305,871
Pretax Income TTM
$-5,156,255
Interest Exp TTM
$238,727
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 0 | -5,700,950 | -5,525,344 | 1,955,913 | 942,759 | 1,013,154 | -4,216,517 |
| Dec 2023 | 0 | -4,526,974 | -5,000,497 | 4,323,369 | 655,252 | 3,668,117 | -3,703,776 |
| Dec 2022 | 0 | -3,557,788 | -3,555,505 | 8,037,420 | 1,119,862 | 6,917,558 | -1,993,814 |
| Dec 2021 | 0 | -4,140,413 | -4,522,934 | 11,059,923 | 1,117,968 | 9,941,955 | -2,798,614 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
| PPCB | Propanc Biopharma, Inc. | $1.44M | $0.63 | — |
| LIFD | LFTD PARTNERS INC. | $1.48M | $0.10 | — |
| GCAN | TRAFALGAR INTERNATIONAL, INC. | $1.60M | $1.61 | — |
| CMND | Clearmind Medicine Inc. | $1.19M | $0.80 | — |
News headlines (Yahoo Finance, 1h cache)
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
2026-04-23 12:15 · Yahoo
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
2026-05-19 12:15 · Yahoo
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
2026-08-20 12:30 · Yahoo
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
2026-06-30 12:30 · Yahoo
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
2026-03-17 12:00 · Yahoo
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
2026-03-10 12:00 · Yahoo
Results from Phase 1 Multiple-Dose Study of PT00114
2025-12-09 13:46 · Yahoo
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
2025-11-27 08:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.